Fusacort 1.2/20mg Gel 10gm

Fusacort 1.2/20mg Gel 10gm contains Betamethasone Valerate (or Betamethasone Dipropionate) and Fusidic Acid, a dual-action topical combination formulated for the treatment of dermatological conditions involving both inflammation and bacterial infection. Betamethasone belongs to the fluorinated corticosteroid class and exerts its effect by binding to intracellular glucocorticoid receptors, suppressing the expression of pro-inflammatory cytokines, reducing vascular permeability, inhibiting the recruitment of immune cells, and downregulating mediators of the allergic and inflammatory response within the skin.

Fusidic Acid is a naturally derived steroid antibiotic obtained from the fungus Fusidium coccineum. It inhibits bacterial protein synthesis by blocking the translocation step of the elongation factor G (EF-G) on the ribosome, leading to bacteriostatic activity. It demonstrates excellent penetration into skin tissue and has a particularly high degree of activity against Staphylococcus aureus, including methicillin-sensitive strains, which are the predominant causative organisms in infected eczema and impetigo.

The combination of Betamethasone and Fusidic Acid in a single topical preparation addresses the two cardinal pathological processes underlying infected inflammatory skin disease, inflammation and infection, simultaneously. This not only simplifies the treatment regimen but also reduces the duration of therapy and improves patient adherence. Fusacort 1.2/20mg Gel 10gm is available as a cream or ointment for topical application and should be used as directed by a doctor, limited in duration and body surface area to minimise systemic corticosteroid absorption.

The uses of Fusacort 1.2/20mg Gel 10gm are as follows:

Infected Eczema (Atopic Dermatitis with Secondary Bacterial Infection)

Treatment of inflamed, itchy skin complicated by Staphylococcal superinfection, a common presentation in atopic individuals.

Impetigo

Topical management of superficial bacterial skin infections, particularly those caused by Staphylococcus aureus or Streptococcus pyogenes, especially when occurring over inflamed skin.

Infected Contact Dermatitis

Management of allergic or irritant contact reactions that have become secondarily infected, causing weeping, crusting, or purulent exudate.

Seborrhoeic Dermatitis with Secondary Infection

Relief of inflamed, scaly skin in seborrhoeic areas, particularly when colonised by bacteria, warrants antibiotic treatment.

Psoriasis with Superimposed Infection

Short-term adjunctive treatment of psoriatic plaques where bacterial superinfection is clinically evident.

Intertrigo with Bacterial Infection

Treatment of inflammatory skin fold conditions complicated by bacterial colonisation, particularly in body folds prone to friction and moisture.

Here are the benefits of Fusacort 1.2/20mg Gel 10gm:

• Dual Action Against Infection and Inflammation: The combination simultaneously eradicates Gram-positive bacteria responsible for secondary skin infections while controlling the erythema, pruritus, oedema, and scaling associated with the underlying inflammatory dermatosis, addressing both disease processes with a single application.

• Rapid Symptom Relief: Betamethasone, being a high-potency corticosteroid, provides prompt reduction of itching, redness, and swelling, offering meaningful symptomatic comfort to patients within the first few days of treatment and improving quality of life significantly.

• Excellent Anti-Staphylococcal Coverage: Fusidic Acid is one of the most active topical agents against Staphylococcus aureus and achieves high tissue concentrations that are bacteriostatic at standard doses, making it well-suited for the primary pathogen responsible for the majority of secondary skin infections.

• Minimised Systemic Side Effects: Topical application concentrates drug delivery at the site of disease, significantly reducing systemic absorption compared to oral agents, and thereby limiting the risks of systemic corticosteroid or antibiotic side effects when used appropriately and for short durations.

• Simplified Treatment Regimen: Using one topical preparation instead of two separate formulations reduces patient burden, simplifies application instructions, and improves adherence, particularly in patients managing multiple skin conditions concurrently.

Like all medicines, Fusacort 1.2/20mg Gel 10gm may cause side effects in some individuals, although many people tolerate it well. Most side effects are mild, localised, and improve after completing the course of treatment.

Common Side Effects

• Skin Burning or Stinging: A transient sensation of warmth, stinging, or tingling at the application site, particularly on broken or inflamed skin; usually resolves within minutes.

• Skin Dryness or Peeling: Mild drying or superficial desquamation at the site of application during or after the treatment course.

• Erythema or Pruritus at Application Site: Mild redness or itching may be noticed at the treated area, especially in individuals with sensitive skin.

Uncommon Side Effects

• Skin Atrophy: Thinning of the skin with prolonged or inappropriate use of the corticosteroid component, especially on the face or in occluded areas.

• Striae (Stretch Marks): Permanent skin streaks resulting from prolonged topical corticosteroid use, more likely in flexural areas and skin folds.

• Telangiectasia: Visible superficial blood vessel dilation from chronic corticosteroid use on delicate skin areas.

Serious Side Effects (Require Immediate Medical Attention)

• Adrenal Suppression: Systemic absorption of Betamethasone over large areas or under occlusion can suppress the hypothalamic-pituitary-adrenal axis, especially in infants and children.

• Severe Allergic Reaction (Contact Sensitisation): Rarely, Fusidic Acid may cause contact allergy presenting as worsening dermatitis, hives, or anaphylaxis; seek emergency care immediately.

• Antibiotic Resistance: Prolonged or repeated use of topical Fusidic Acid can lead to the emergence of resistant Staphylococcal strains, which may complicate future treatment; always complete the prescribed duration and avoid unnecessary re-use.

Always consult your doctor if you notice any unusual symptoms while taking Fusacort 1.2/20mg Gel 10gm.

To ensure optimal therapeutic effect and minimise local and systemic side effects, Fusacort 1.2/20mg Gel 10gm should be applied correctly and strictly as directed by your doctor.

• Apply a thin layer of Fusacort 1.2/20mg Gel 10gm to the affected area only, as prescribed. Do not apply to healthy, unaffected skin.

• Wash and gently dry the affected area before applying the cream or ointment.

• Use the fingertip unit as a guide: one fingertip unit covers an area approximately the size of two adult palms.

• Do not cover the treated area with airtight dressings or bandages unless specifically instructed by your doctor, as occlusion significantly increases systemic absorption.

• Avoid application to the eyes, mouth, or mucous membranes. If accidental contact occurs, rinse thoroughly with water.

• Wash hands thoroughly after application unless the hands themselves are the treated area.

• Do not use for longer than prescribed. Typical courses are 7 to 14 days; prolonged use must be supervised by a doctor.

• Do not use on the face for extended periods; if facial application is prescribed, use the minimum effective amount for the shortest duration.

Fusacort 1.2/20mg Gel 10gm works through two distinct and complementary mechanisms acting on the skin.

Betamethasone is a fluorinated synthetic corticosteroid that, upon penetrating the epidermis, binds to cytoplasmic glucocorticoid receptors. The drug-receptor complex translocates into the nucleus and modulates gene transcription, increasing the expression of anti-inflammatory proteins (lipocortins) and suppressing the transcription of pro-inflammatory cytokines including interleukin-1, interleukin-6, and tumour necrosis factor-alpha. It also inhibits phospholipase A2, thereby reducing the production of arachidonic acid and its downstream pro-inflammatory metabolites — prostaglandins, leukotrienes, and thromboxanes. This results in decreased vasodilation, reduced oedema, suppression of immune cell migration, and alleviation of pruritus and erythema at the site of inflammation.

Fusidic Acid exerts its antibacterial effect by selectively inhibiting bacterial protein synthesis. It blocks the translocation step on the ribosome by stabilising the complex formed between elongation factor G (EF-G), GDP, and the ribosome, thereby preventing the movement of transfer RNA and messenger RNA and halting the elongation of the peptide chain. This leads to bacteriostatic inhibition of bacterial growth. Because its mechanism is structurally distinct from other antibiotics, Fusidic Acid retains activity against strains resistant to many other classes, and it demonstrates excellent penetration into skin tissue, abscesses, and inflamed dermis, making it highly effective locally.

Together, these mechanisms provide coordinated control of both the immunological inflammatory response and the bacterial pathogen, breaking the cycle of infection-driven worsening of dermatological disease.

A few practical measures can significantly improve treatment outcomes and minimise the risk of side effects.

• Never apply to the face, groin, or armpits unless specifically directed by your doctor, as these areas are more susceptible to atrophy with potent corticosteroids.

• Complete the full prescribed course of treatment to prevent re-emergence of infection or antibiotic resistance.

• Do not share this medication with others, even if their skin condition appears similar.

• Avoid using other topical products, cosmetics, or emollients on the treated area without your doctor’s advice, as they may alter drug absorption.

• Keep nails short and clean to avoid scratching the affected area, which can introduce further bacteria and worsen the infection.

• Attend follow-up reviews as scheduled so your doctor can monitor treatment response and decide whether to continue, taper, or step down therapy.

• If symptoms worsen or do not improve within one week of starting treatment, seek medical advice promptly as an alternative diagnosis or treatment may be required.

Proper storage helps maintain the effectiveness and safety of Fusacort 1.2/20mg Gel 10gm throughout its shelf life.

• Store at room temperature below 25°C, away from direct heat and sunlight.

• Do not refrigerate or freeze the cream or ointment; cold temperatures can alter the formulation and reduce effectiveness.

• Keep the tube tightly closed when not in use to prevent contamination and drying out of the product.

• Keep out of reach of children.

• Do not use after the expiry date printed on the tube or carton.

Fusacort 1.2/20mg Gel 10gm does not have significant interactions with foods or beverages when used topically. However:

• If applied over large body surface areas, systemic absorption of Betamethasone may be sufficient to interact metabolically; patients with diabetes should monitor blood glucose carefully.

• Avoid applying alcohol-based toners, astringents, or skin treatments immediately before or after Fusacort 1.2/20mg Gel 10gm on broken or infected skin, as these may cause significant irritation.

Betamethasone + Fusidic Acid may interact with:

• Systemic Corticosteroids: Additive immunosuppressive and adrenal effects with concurrent topical and systemic corticosteroid use over large skin areas.

• Statins: Fusidic Acid can inhibit CYP3A4 and may increase the risk of myopathy or rhabdomyolysis when used concurrently with statins.

• Antifungals: May increase systemic exposure to the corticosteroid component by inhibiting its hepatic metabolism, raising the risk of systemic corticosteroid side effects.

• Other Topical Antibiotics: Concurrent application of multiple topical antibiotics on the same area is generally not recommended and may increase the risk of resistance or local irritation.

• Immunosuppressants (e.g. tacrolimus, cyclosporin): Combined immunosuppression with topical corticosteroids may increase susceptibility to local or systemic infections.

Fusacort 1.2/20mg Gel 10gm should be used carefully in:

• Fungal or Viral Skin Infections: Betamethasone can mask or worsen untreated fungal infections (e.g., tinea) or viral infections (e.g., herpes simplex).

• Diabetes Mellitus: Systemic absorption of the corticosteroid through the skin may impair glycaemic control, particularly with widespread or prolonged use.

• Glaucoma or Ocular Hypertension: Topical corticosteroid application near or around the eyes may raise intraocular pressure.

• Psoriasis: Intensive or prolonged corticosteroid use on psoriatic plaques can lead to rebound flare upon cessation.

• Hepatic Impairment: Fusidic acid is metabolised in the liver.

The dose and frequency of application depend on the severity and extent of the skin condition, the patient’s age, and the formulation used. Typically, a thin layer is applied to the affected area two to three times daily for a period not exceeding two weeks, or as directed by the prescribing physician. Always follow medical instructions carefully and do not apply more frequently or over a larger area than prescribed.

If you miss a scheduled application of Fusacort 1.2/20mg Gel 10gm, apply it as soon as you remember, unless it is almost time for your next application. In that case, skip the missed dose and continue with your regular schedule. Never double the amount to compensate for a missed application.